Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV). Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration. However, NS5A has no known enzymat...

Full description

Saved in:
Bibliographic Details
Main Authors: Guedj, Jeremie, Dahari, Harel, Rong, Libin, Sansone, Natasha D., Nettles, Richard E., Cotler, Scott J., Layden, Thomas J., Uprichard, Susan L., Perelson, Alan S.
Format: Artigo
Language:Inglês
Published: National Academy of Sciences 2013
Subjects:
Biological Sciences
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3593898/
https://ncbi.nlm.nih.gov/pubmed/23431163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1203110110
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items